FZD10 Carried by Exosomes Sustains Cancer Cell Proliferation.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
25 07 2019
Historique:
received: 08 07 2019
revised: 21 07 2019
accepted: 23 07 2019
entrez: 28 7 2019
pubmed: 28 7 2019
medline: 10 4 2020
Statut: epublish

Résumé

Extracellular vesicles (EVs) are involved in intercellular communication during carcinogenesis, and cancer cells are able to secrete EVs, in particular exosomes containing molecules, that can be transferred to recipient cells to induce pathological processes and significant modifications, as metastasis, increase of proliferation, and carcinogenesis evolution. FZD proteins, a family of receptors comprised in the Wnt signaling pathway, play an important role in carcinogenesis of the gastroenteric tract. Here, a still unknown role of Frizzled 10 (FZD10) protein was identified. In particular, the presence of FZD10 and FZD10-mRNA in exosomes extracted from culture medium of the untreated colorectal, gastric, hepatic, and cholangio cancer cell lines, was detected. A substantial reduction in the FZD10 and FZD10-mRNA level was achieved in FZD10-mRNA silenced cells and in their corresponding exosomes. Concomitantly, a significant decrease in viability of the silenced cells compared to their respective controls was observed. Notably, the incubation of silenced cells with the exosomes extracted from culture medium of the same untreated cells promoted the restoration of the cell viability and, also, of the FZD10 and FZD10-mRNA level, thus indicating that the FZD10 and FZD10-mRNA delivering exosomes may be potential messengers of cancer reactivation and play an active role in long-distance metastatization.

Identifiants

pubmed: 31349740
pii: cells8080777
doi: 10.3390/cells8080777
pmc: PMC6721576
pii:
doi:

Substances chimiques

FZD10 protein, human 0
Frizzled Receptors 0
RNA, Messenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Références

Nat Rev Drug Discov. 2013 May;12(5):347-57
pubmed: 23584393
Oncogene. 2009 Feb 26;28(8):1110-20
pubmed: 19137009
Nat Rev Drug Discov. 2011 Jan;10(1):47-60
pubmed: 21193867
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Bioelectrochemistry. 2019 Apr;126:92-98
pubmed: 30530260
Int J Mol Sci. 2018 May 22;19(5):
pubmed: 29789460
Hepatology. 2008 Jun;47(6):2059-67
pubmed: 18506891
Oncotarget. 2017 Dec 12;9(1):824-830
pubmed: 29416658
J Extracell Vesicles. 2015 Jul 17;4:27031
pubmed: 26194179
Curr Opin Cell Biol. 2004 Aug;16(4):415-21
pubmed: 15261674
Cell Oncol (Dordr). 2018 Jun;41(3):223-252
pubmed: 29667069
Cell Signal. 2018 Jan;41:65-74
pubmed: 28931490
Nat Rev Cancer. 2007 Feb;7(2):79-94
pubmed: 17251915
Stem Cells Transl Med. 2017 Aug;6(8):1730-1739
pubmed: 28714557
Apoptosis. 2011 Jan;16(1):1-12
pubmed: 20717727
Int J Mol Sci. 2016 Aug 12;17(8):
pubmed: 27529230
Nat Rev Drug Discov. 2017 Sep;16(9):787-810
pubmed: 28706220
Oncol Lett. 2018 Oct;16(4):5243-5248
pubmed: 30250594
J Biol Chem. 2009 Dec 4;284(49):34211-22
pubmed: 19801663
Cancer Metastasis Rev. 2018 Mar;37(1):147-157
pubmed: 29222765
J Extracell Vesicles. 2015 Dec 31;4:30087
pubmed: 26725829
J Exp Clin Cancer Res. 2018 Sep 3;37(1):211
pubmed: 30176945
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
BMB Rep. 2014 Oct;47(10):531-9
pubmed: 25104400
Anal Chem. 2017 Feb 21;89(4):2488-2496
pubmed: 28192938
EMBO J. 2010 Oct 6;29(19):3236-48
pubmed: 20736927
PLoS One. 2011 Feb 25;6(2):e16899
pubmed: 21364924
J Oncol. 2019 Jun 2;2019:2715968
pubmed: 31275379
Cancer Immunol Immunother. 2006 Jul;55(7):808-18
pubmed: 16283305
J Extracell Vesicles. 2018 Mar 01;7(1):1440131
pubmed: 29535849
Analyst. 2013 Feb 21;138(4):1015-9
pubmed: 23304693
Cancer Sci. 2009 Mar;100(3):405-12
pubmed: 19134005
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Anal Chim Acta. 2018 Nov 22;1032:114-121
pubmed: 30143208
Mol Pharmacol. 2003 Jun;63(6):1256-72
pubmed: 12761335
Annu Rev Pharmacol Toxicol. 2015;55:439-464
pubmed: 25292428
Cancer Res. 2005 Jun 1;65(11):4817-26
pubmed: 15930302
J Mater Chem B. 2019 Feb 7;7(5):768-777
pubmed: 32254851
Nat Cell Biol. 2012 Oct;14(10):1036-45
pubmed: 22983114

Auteurs

Maria Principia Scavo (MP)

Personalized Medicine Laboratory, National Institute of Gastroenterology "S. De Bellis", Via Turi 27, Castellana Grotte, 70013 Bari, Italy. maria.scavo@irccsdebellis.it.

Nicoletta Depalo (N)

Institute for Chemical and Physical Processes (IPCF)-CNR SS Bari, Via Orabona 4, 70126 Bari, Italy.

Federica Rizzi (F)

Institute for Chemical and Physical Processes (IPCF)-CNR SS Bari, Via Orabona 4, 70126 Bari, Italy.

Chiara Ingrosso (C)

Institute for Chemical and Physical Processes (IPCF)-CNR SS Bari, Via Orabona 4, 70126 Bari, Italy.

Elisabetta Fanizza (E)

Institute for Chemical and Physical Processes (IPCF)-CNR SS Bari, Via Orabona 4, 70126 Bari, Italy.
Dipartimento di Chimica, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70126 Bari, Italy.

Annarita Chieti (A)

Personalized Medicine Laboratory, National Institute of Gastroenterology "S. De Bellis", Via Turi 27, Castellana Grotte, 70013 Bari, Italy.

Caterina Messa (C)

Laboratory of Clinical Biochemistry, National Institute of Gastroenterology "S. De Bellis", Via Turi 27, Castellana Grotte, 70013 Bari, Italy.

Nunzio Denora (N)

Institute for Chemical and Physical Processes (IPCF)-CNR SS Bari, Via Orabona 4, 70126 Bari, Italy.
Dipartimento di Farmacia, Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70126 Bari, Italy.

Valentino Laquintana (V)

Dipartimento di Farmacia, Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70126 Bari, Italy.

Marinella Striccoli (M)

Institute for Chemical and Physical Processes (IPCF)-CNR SS Bari, Via Orabona 4, 70126 Bari, Italy.

Maria Lucia Curri (ML)

Institute for Chemical and Physical Processes (IPCF)-CNR SS Bari, Via Orabona 4, 70126 Bari, Italy.
Dipartimento di Chimica, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70126 Bari, Italy.

Gianluigi Giannelli (G)

Personalized Medicine Laboratory, National Institute of Gastroenterology "S. De Bellis", Via Turi 27, Castellana Grotte, 70013 Bari, Italy. gianluigi.giannelli@irccsdebellis.it.
National Institute of Gastroenterology "S. De Bellis", Scientific Direction, Via Turi 27, Castellana Grotte 70013 Bari, Italy. gianluigi.giannelli@irccsdebellis.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH